Weight Loss in Adults Using Semaglutide (Real-world Study)

May 30, 2026 updated by: Novo Nordisk A/S

Real-world Weight Outcomes in Adults Treated With Semaglutide s.c. 1.0 mg or 1.7 mg for Weight Management: a Non-interventional Cohort Study

The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

35000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United Kingdom
      • London, United Kingdom
        • Recruiting
        • Novo Nordisk Investigational Site
  • United States
    • Washington
      • Seattle, Washington, United States, 98039
        • Recruiting
        • Novo Nordisk Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population comprises adults initiating semaglutide in routine clinical practice.

Description

Inclusion Criteria:

  • Initiation of semaglutide for weight management during the study period.
  • Age more than or equal to (≥) 18 at treatment initiation
  • Baseline body mass index (BMI) ≥27 and less than (<) 30 kilogram per meter square (kg/m^2) with at least one weight-related comorbidity, or BMI ≥30 kg/m^2.
  • Other inclusion criteria as defined in the protocol are applicable.

Exclusion Criteria:

  • Prior use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) based medication or other obesity management medication (OMMs).
  • Bariatric surgery at baseline.
  • Diabetes at baseline.
  • Pregnancy at baseline.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Semaglutide
Adults initiating semaglutide in routine clinical care and assigned to 0.5, 1.0, 1.7 or 2.4 mg at approximately Week 20. Participants are followed from treatment initiation up to 68 weeks using data collected during routine clinical practice. No study-specific interventions, visits, or procedures are performed. Data are derived from secondary use of routinely collected healthcare data.
Drug: Semaglutide
This is a retrospective, non-interventional study; therefore, no intervention was administered as part of the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in body weight
Time Frame: From index date (day 0) to week 68 (day 476)
Measured as kilogram (kg)
From index date (day 0) to week 68 (day 476)
Change in body weight
Time Frame: From index date (day 0) to week 68 (day 476)
Measured as percentage (%)
From index date (day 0) to week 68 (day 476)
Proportion of individuals achieving a clinically meaningful weight loss
Time Frame: From index date (day 0) to week 68 (day 476)
Binary (yes/no): estimated ≥5% reduction from baseline body weight
From index date (day 0) to week 68 (day 476)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Novo Nordisk A/S

Investigators

  • Study Director: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 12, 2026

Primary Completion (Estimated)

June 1, 2026

Study Completion (Estimated)

June 1, 2026

Study Registration Dates

First Submitted

May 30, 2026

First Submitted That Met QC Criteria

May 30, 2026

First Posted (Actual)

June 4, 2026

Study Record Updates

Last Update Posted (Actual)

June 4, 2026

Last Update Submitted That Met QC Criteria

May 30, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NN9536-8874
  • U1111-1338-2016 (Other Identifier: World Health Organization (WHO))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Drug and device information, study documents

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Semaglutide

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe